Edward J. Dulac III, who serves as executive vice president and chief financial officer at Intellia Therapeutics, Inc. (NASDAQ:NTLA), completed a transaction involving the disposal of 8,111 shares of the company's common stock on July 22, 2026. The shares were sold at prices ranging from $11.25 to $11.28 per share, resulting in a total transaction value of $91,248. This sale was classified as a mandatory "sell-to-cover" mechanism designed to fulfill tax withholding requirements associated with the vesting of restricted stock units. According to the company disclosure, the transaction does not reflect a discretionary decision by Mr. Dulac to reduce his equity position.
After the transaction, Mr. Dulac's beneficial ownership of Intellia Therapeutics common stock stood at 148,175 shares. The company's financial position remains solid, with a balance sheet characterized by cash holdings that exceed its debt obligations. Data from InvestingPro indicates a current ratio of 6.1, suggesting strong short-term liquidity. Despite this financial strength, Intellia's stock has experienced recent downward pressure, declining roughly 6% over the past week. The stock is currently trading at $10.73, a level well below its 52-week high of $28.25.
Market analyst opinions on Intellia Therapeutics are currently divided. Wolfe Research downgraded the stock to an Underperform rating, citing concerns regarding current valuation. The firm set a price target of $9.00 and projected cumulative revenue of $4.5 billion for lonvo-z, a figure that falls below consensus estimates of $6.5 billion. Conversely, Canaccord Genuity reiterated its Buy rating with a $49.00 price target, referencing additional Phase 3 data from the HAELO study that demonstrated positive outcomes for lonvo-z in treating hereditary angioedema. H.C. Wainwright also maintained a Buy rating, assigning a $25.00 price target and noting the trial's success in reducing monthly attacks by 87% compared to a placebo. Citizens retained a Market Outperform rating with a $30.00 price target, following the presentation of further positive data from the HAELO trial.
Options activity for Intellia has seen a notable increase, with a total of 7,041 contracts traded recently. The juxtaposition of cautious valuation assessments from some analysts against optimistic trial data evaluations from others highlights the complex environment surrounding the stock. The recent developments reflect a mix of cautious valuation assessments and optimistic trial data evaluations from various analyst firms.